Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Antibe Therapeutics Inc (ATE.VN)

Antibe Therapeutics Inc (ATE.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Antibe Therapeutics Inc 15 Prince Arthur Avenue Toronto ON M5R 1B2 CAN

P: 416-922-3460

Description:

Antibe Therapeutics Inc develops safer, non-addictive medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. The company's drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Its operating segment includes Antibe and Citagenix. The company generates maximum revenue from Citagenix segment and geographically from Canada. Citagenix segment is a marketer and distributor of regenerative medicines serving the dental and orthopaedic market places.

Key Statistics

Overview:

Market Capitalization, $K 148,403
Shares Outstanding, K 385,462
Annual Sales, $ 0 K
Annual Net Income, $ 0 K
% of Institutional Shareholders 0.06%

Growth:

1-Year Return -6.90%
3-Year Return 326.32%
5-Year Return 125.00%
5-Year Revenue Growth 246.63%

Per-Share Information:

Latest Earnings Date 11/26/20
Earnings Per Share ttm -0.08
Dividend Payout Ratio 0.00%

ATE.VN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -115.93%
Return-on-Assets % -81.07%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 4.82
Book Value/Share N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar